The Biostatistics Shared Resource (BSR) of the Mayo Clinic Cancer Center (MCCC), under the leadership of Dr. Amylou Dueck, PhD since 2016, has provided expert statistical collaboration with MCCC investigators for over 40 years. The BSR focuses on the development and conduct of peer-reviewed Cancer Center research that encompasses basic science, clinical trials, epidemiologic research, translational, health outcomes, and other educational research. The primary use of Cancer Center Support Grant (CCSG) funds within the BSR is to support statistical collaboration on pilot projects by assisting investigators to develop prioritized research projects leading to external funding and to support emerging needs for statistical collaboration on MCCC prioritized projects. Funding is primarily provided as salary support to key faculty members to collaborate with MCCC members at no charge. Funding is also provided to BSR senior Master's level statisticians to work on prioritized MCCC projects. In the current grant period, the BSR has developed expertise in precision medicine clinical trials, become worldwide leaders in pooled analyses and surrogate endpoints, and have expanded leadership to the Arizona site. BSR faculty members include statistical methodological research leaders in clinical trial design/conduct, high dimensional data, statistical genetics, quality of life/patient-reported outcomes, pooled analysis, and surrogate endpoints. The BSR has 3 focus areas (teams) coordinated together into a well-organized, efficient core. These are: (1) a Clinical Trials team responsible for cancer clinical trials, associated translational research, and patient and public education research projects; (2) a Population Science/Computational Genomics team responsible for statistical collaboration and data management support for high dimensional data analyses and cancer observational studies, including genetic and molecular epidemiology; and (3) a Quality of Life team responsible for collaboration, measurement tools, and analysis for MCCC investigators investigating the impact of clinical and psychosocial interventions on cancer patients, families, caregivers, and others. The BSR has been remarkably productive, with authorship on 1,066 peer- reviewed cancer-related publications and collaborations on 89 NIH or NIH-equivalent cancer-related grants in the current grant period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113600
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066
Kalli, Kimberly R; Block, Matthew S; Kasi, Pashtoon M et al. (2018) Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients. Clin Cancer Res 24:3014-3025
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Langlais, Blake T; Geyer, Holly; Scherber, Robyn et al. (2018) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma :1-7

Showing the most recent 10 out of 1129 publications